These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149 [TBL] [Abstract][Full Text] [Related]
46. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
47. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database. Butts RJ; Dipchand AI; Sutcliffe D; Bano M; Dimas V; Morrow R; Das B; Kirk R Pediatr Transplant; 2018 Jun; 22(4):e13190. PubMed ID: 29878688 [TBL] [Abstract][Full Text] [Related]
48. A contemporary analysis of induction immunosuppression in pediatric lung transplant recipients. Hayes D; Kirkby S; Wehr AM; Lehman AM; McConnell PI; Galantowicz M; Higgins RS; Whitson BA Transpl Int; 2014 Feb; 27(2):211-8. PubMed ID: 24236829 [TBL] [Abstract][Full Text] [Related]
49. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Magliocca JF; Odorico JS; Pirsch JD; Becker YT; Knechtle SJ; Leverson GE; Sollinger HW Am J Transplant; 2008 Aug; 8(8):1702-10. PubMed ID: 18694474 [TBL] [Abstract][Full Text] [Related]
51. Basiliximab induction versus no induction in adult heart transplantation. Rudzik KN; Rivosecchi RM; Palmer BA; Hickey GW; Huston JH; Keebler ME; Kaczorowski DJ; Horn ET Clin Transplant; 2023 May; 37(5):e14937. PubMed ID: 36793206 [TBL] [Abstract][Full Text] [Related]
52. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience. Florescu DF; Seaman JA; Kalil AC; Qiu F; Bremers D; Westphal SG Transplant Proc; 2021 Apr; 53(3):1058-1063. PubMed ID: 32921434 [TBL] [Abstract][Full Text] [Related]
53. The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome. DerHovanessian A; Weigt SS; Palchevskiy V; Shino MY; Sayah DM; Gregson AL; Noble PW; Palmer SM; Fishbein MC; Kubak BM; Ardehali A; Ross DJ; Saggar R; Lynch JP; Elashoff RM; Belperio JA Am J Transplant; 2016 Feb; 16(2):640-9. PubMed ID: 26461171 [TBL] [Abstract][Full Text] [Related]
54. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). Fisher AJ; Wardle J; Dark JH; Corris PA J Heart Lung Transplant; 2002 Nov; 21(11):1206-12. PubMed ID: 12431494 [TBL] [Abstract][Full Text] [Related]
55. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276 [TBL] [Abstract][Full Text] [Related]
56. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience. Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348 [TBL] [Abstract][Full Text] [Related]
57. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Finlen Copeland CA; Snyder LD; Zaas DW; Turbyfill WJ; Davis WA; Palmer SM Am J Respir Crit Care Med; 2010 Sep; 182(6):784-9. PubMed ID: 20508211 [TBL] [Abstract][Full Text] [Related]
58. Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation. Moore CA; Pilewski JM; Venkataramanan R; Robinson KM; Morrell MR; Wisniewski SR; Zeevi A; McDyer JF; Ensor CR Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28273385 [TBL] [Abstract][Full Text] [Related]
59. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812 [TBL] [Abstract][Full Text] [Related]